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Abstract 
The aim of this study was to evaluate the significance of performing patient specification 
quality assurance for patients diagnosed with glioblastoma multiforme treated with in-
tensity modulated radiation therapy. The study evaluated ten intensity modulated radi-
ation therapy treatment plans using 10 MV beams, a total dose of 60 Gy (2 Gy/fraction, 
five fractions a week for a total of six weeks treatment). For the quality assurance proto-
col  we  used  a  two-dimensional  ionization-chamber  array  (2D-ARRAY).  The  results 
showed  a  very  good  agreement  between  the  measured  dose  and  the  pretreatment 
planned dose. All the plans passed >95% gamma criterion with pixels within 5% dose 
difference and 3 mm distance to agreement. We concluded that using the 2D-ARRAY ion 
chamber for intensity modulated radiation therapy is an important step for intensity 
modulated radiation therapy treatment plans, and this study has shown that our treat-
ment planning for intensity modulated radiation therapy is accurately done. 
Key words: Photon-beam dose calculation; quality assurance, intensity modulated radiation ther-
apy, dose veriﬁcation, gamma index, glioblastoma multiforme. 
Introduction 
Glioblastoma  multiforme  (GBM)  is  the  most 
common  malignant  tumor  of  the  subcortical  white 
matter  of  the  cerebral  hemisphere  in  adults.  It  ac-
counts for 12%-15% of all primary brain tumors [1]. 
The  treatment  of  GBM  involves  surgical  resection, 
which is the first therapeutic modality for GBM, fol-
lowed by radiotherapy that may be accompanied by 
adjuvant chemotherapy [2]. In general, patients with 
GBM have poor prognosis with about 20% of patients 
surviving beyond 2 years [2]. However, some factors 
may be associated with a longer survival rate. These 
factors include younger age, gender, unilateral tumor, 
a high Karnofsky score, size of the tumor, extent of 
disease, and adjuvant treatments with chemotherapy 
such as temozolomide (TMZ) [3].  
In  recent  years,  the  development  of 
state-of-the-art radiation therapy and recent advances 
in  chemotherapy  have  increased  the  chances  for  a 
good prognosis for GBM patients [4]. Intensity mod-
ulated radiotherapy (IMRT) allows for a high dose of 
radiation to be delivered to the tumor while permit-
ting maximal sparing of normal tissue which reduces 
the radiation toxicity [5-9]. In the case of glioblastoma 
multiforme, IMRT has shown the potential to deliver 
a highly conformal dose to the target while minimiz-
ing dose to the organs at risk (OAR) such as the optic 
chiasm [10]. This can allow for dose escalation, while 
on the other hand, also increase local control [6, 7,11]. 
Treatment  with  IMRT  fields  involves  the  complex 
movement  of  a  multileaf  collimator  (MLC)  which 
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consists of many small and irregular multileaf fields 
or segments that can be delivered in two main mo-
dalities, namely segmental IMRT step-and-shoot (SS) 
or dynamic IMRT (sliding window) [12]. In the IMRT 
step-and-shoot (SS) technique, the shape of the leaves 
stays  constant  while  the  radiation  beam  is  on  and 
changes when the radiation beam is off, while in the 
dynamic  sliding  window  technique  each  leaf  pair 
moves continuously in one direction with independ-
ent speeds while the radiation beam is on [13].  
IMRT dose distributions have the characteristics 
of complex 3-dimensional dose gradients and a time- 
dependent  ﬂuence  delivery  [14].  These  complex 
characterizations  make  quality  assurance  for  every 
IMRT  treatment  compulsory.  The  goals  of  the  pre-
treatment quality assurance are to assure the precision 
of the IMRT treatment plan and the application of the 
prescribed dose from the plan [13]. As a consequence 
of the complexity of the IMRT technique, additional 
dose checking methods are required to confirm  the 
exact calculation of the dose for all patients treated 
with IMRT [15, 16]. The most common applied dose 
evaluation  tools  encompass  a  direct  comparison  of 
dose  differences  that  have  a  comparison  of  dis-
tance-to-agreement  (DTA)  between  the  measured 
dose and the calculated dose distributions from the 
planning system [16, 17].  
The checking procedure for IMRT includes sev-
eral  steps  which  then  lead  to  the  quality  assurance 
(QA) for the whole IMRT treatment plan. These steps 
include  the  multileaf  collimator  (MLC)  QA,  the 
measurements of individual patient fluence maps, the 
calibration of the tools used, and the reproducibility 
of patient positioning [18]. The planned dose fluence 
is compared with deliverable dose fluence, usually by 
using  a  two-dimensional  array  with  ionization 
chambers,  electronic  portal  imaging  devices  (EPID), 
or radiochromic film named “Gafchromic EBT film” 
[19, 20]. In this study we used a two-dimensional ar-
ray with 729 ionization chambers, which is a portal 
dose device for IMRT plan verification. 
Materials and Methods 
Our  IMRT  pretreatment  dose  verification 
method consisted of the following two independent 
measurements: first, point dose measurements at the 
isocenter  using  a  two-dimensional  detector  matrix 
with  729  ionization  chambers  (2D-ARRAY)  (PTW, 
Freiburg,  Germany);  and  second,  using  RadCalc 
(RadCalc, Lifeline Software, Inc., Tyler, TX) to check 
independent monitor units (MU) for each beam. Pre-
treatment IMRT plans for ten patients diagnosed with 
GBM brain tumors were selected. For each of the ten 
pretreatment  plans,  verification  IMRT  plans  were 
created  using  a  Varian  Eclipse  external  beam  treat-
ment  planning  system  (Eclipse  TPS)  (8.1.18,  Varian 
Medical Systems Inc., Palo Alto, CA). All IMRT veri-
fication plans have the same dosimetric parameters of 
the original plans. The dose was calculated using the 
Pencil Beam Convolution (PBC) algorithm built-in in 
the  3-dimensional  treatment  planning  system.  The 
verification plan for each patient was created to start 
the verification process. All treatment parameters, i.e., 
monitor units, field sizes, gantry angles, and leaf mo-
tion instructions, are stored in the database of ARIA 
Oncology  (Varian  Medical  Systems  Inc.,  Palo  Alto, 
CA), which is an oncology-specific electronic medical 
record (EMR) that manages clinical activities such as 
radiation treatment.  
The system is connected through a network to all 
of  the  treatment  units.  The  two-dimensional  array 
used  in  this  investigation  (2D-ARRAY)  is  equipped 
with  729  vented  plane  parallel  ion  chambers.  Each 
detector covers an area of 5 x 5 mm2 and the measur-
ing depth is at 5 mm water. The sensitive volume of 
each chamber is 0.125 cm3. These ionization chambers 
are uniformly arranged in a 27 × 27 matrix with an 
active area of 27 × 27 cm2 and dimensional area of 22 
mm x 300 mm x 420 mm, interface: 80 mm x 250 mm x 
300 mm, allowing absolute dose and dose rate meas-
urements of high-energy photon beams.  
The  2D-ARRAY  chamber  is  calibrated  using  a 
setup  of  10  cm  x10  cm  field  size,  100  MU,  10  MV 
beams at a depth of 10 cm, and a dose rate of 300 
cGy/MU.  In  favor  of  the  verification  plans,  the 
2D-ARRAY setup consists of three solid water slabs of 
polymethyl  methacrylate  (PMMA)  with  deferent 
thicknesses of 3 cm, 4 cm and 1 cm. 
The 3 cm thickness slab was used as a backscat-
ter phantom, where the other two slabs with a total 
thickness of 10 cm was used as a buildup phantom. 
The 2D-ARRAYchamber center was aligned with the 
isocenter of the plan. The 2D planar dose distribution 
was calculated at a 10 cm depth in the phantom using 
1 mm pixel-dose grid resolution, and the point dose 
was calculated at the isocenter; whereas the reference 
point was 5 mm behind surface. The individual fields 
are radiated in gantry and collimator position of 0° on 
the array and source-to-surface distance (SSD) of 94.5 
cm, using dynamic multileaf collimation on a Varian 
linear  accelerator  Clinac  2100EX  equipped  with  the 
120-leaf  Millennium  MLC  (Varian  Medical  Systems 
Inc., Palo Alto, CA). The MLC system has 60 pairs of 
leaves in each bank and MLC leaf width projected at 
isocenter  is  1  cm.  The  leaf  ends  are  rounded.  The 
2D-ARRAY chamber is connected to a laptop outside 
the treatment room which runs software from PTW.  Int. J. Med. Sci. 2011, 8 
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The  software  is  MatrixScan  (PTW-Verisoft  3.1) 
which  records  the  measurements  with  the 
2D-ARRAY. Prior to the treatment the temperature, 
pressure, and a correction factor for the machine is 
entered into the MatrixScan software. Each beam of 
the  treatment  plan  is  delivered  to  the  2D-ARRAY 
chamber, thus the dose at some reference points can 
be calculated. The measured dose distributions were 
then compared to those calculated by the Eclipse TPS. 
The IMRT treatment plans for each of the ten patients 
consisted of 5 to 11 beams using 10 MV beams with 
total dose of 60 Gy and a dose of 2.0 Gy. Every field is 
irradiated  in  each  plan  one  after  another  on  the 
2D-ARRAY  without  interruptions  or  entering  the 
treatment room and the combined dose is measured, 
reflecting the contribution from all beams for every 
plan.  The  measured  dose  by  2D-ARRAY  was  com-
pared with the planned dose using verification soft-
ware  based  on  the  gamma  index  criterion  [19,20]. 
Comparisons between measured and calculated dose 
distributions  are  reported  as  dose  difference  (DD) 
(pixels  within  5%),  distance  to  agreement  (DTA)  (3 
mm), as well as gamma values (γ) (dose 3%, distance 3 
mm).  
Statistical analysis 
Data  from  each  sample  were  run  in  duplicate 
and expressed as means ± SD (cGy, n = 10 patients). 
Means were considered significantly different if P < 
0.05. Statistical analysis was performed by means of a 
GraphPad  Prism™  package  for  personal  computers 
(GraphPad Software, Inc., San Diego, USA) and fig-
ures were drawn using the GraFitTM package for per-
sonal computers (Erithacus Software Limited, Surrey, 
UK).  An  ANOVA  analysis  using  Tukey’s  test  for 
multiple comparison tests was performed on the data. 
Results 
In this study we evaluated our QA system for 
IMRT plans that are going to be used to treat patients 
with GBM brain tumors. Presently, we perform rou-
tine QA measurements for each IMRT patient either 
immediately prior to the treatment or shortly after the 
first  treatment.  Table  1  shows  the  total  number  of 
IMRT  fields  for  the  ten  selected  treatment  plans 
measured, the fractional dose for each plan, and the 
fractional measured dose by 2D-ARRAY. Table 1 also 
shows the percentage dose different between the TPS 
and the VeriSoft software measured dose in addition 
to the percentage of pixels passing gamma criterion. 
The  overall  study  result  is  shown  in  Figure  1.  The 
average dose difference between planned and meas-
ured dose was  -0.28% with a standard deviation of 
1.06. Considering that the passing criteria for IMRT 
plans  is  based  on  the  percentage  of  pixels  passing 
gamma index >95% within dose difference (pixels is 
within 5%), and distance to agreement dose is 3 mm, 
all  of  our  ten  selected  treatment  plans  passed  the 
gamma analysis test  with an average of 97% pixels 
with an SD of 0.015.  
 
 
 
Figure 1: This graph shows the mean ± SD for the 10 patients of the prescribed dose and measured doses using the 2D-ARRAY 
ion chamber. There was no significant difference (ns) between the target fraction planned dose using TPS with either 
2D-ARRAY or the dose that been calculated using RadCal. (ANOVA analysis, Tukey’s test for multiple comparison tests). 
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Table 1: This data shows the fractional dose for the planned and measured radiation treatment, the RadCalc cal-
culations, the % dose difference between TPS and VeriSoft software measured dose, and the % of pixels passing 
gamma criterion for the 10 patient treatment plans 
Patient’s fields numbers  Fraction Planned 
Dose, cGy 
2D-ARRAY 
Measured dose, 
cGy 
% dose difference between 
TPS and VeriSoft software 
measured dose 
% of pixels passing gamma 
criterion 
5  200.0  199.80   -0.10 %  99% 
8  219.2  219.85   0.29%  97% 
11  219.2  218.90  -0.27%  96% 
9  200.0  200.70   0.35%  97% 
8  219.2  218.50  -0.31%  97% 
11  200.0  200.00   0.00%  100% 
11  200.0  199.80  -0.10%  99% 
8  200.0  198.90  -0.55%  97% 
5  200.0  199.20  -0.40%  97% 
7  200.0  200.50  0.25%  95% 
IMRT fields total of = 83 
 
Average Dose=205.73 
cGy 
Average Dose =205.615 
cGy 
SD= 0.00307  SD=0.0151 
 
 
Discussion 
Glioblastoma  multiforme  (GBM)  is  the  most 
frequently encountered and most malignant form of 
brain tumor, with a poor prognosis and low life ex-
pectancy [21] Intensity modulated radiation therapy 
(IMRT)  is  a  new  development  of  conformal  radio-
therapy which shows a better outcome for treatment, 
with a better sparing of the normal brain tissue and 
other critical structures [19]. IMRT treatment plans are 
complex radiotherapy treatment plans that require a 
comprehensive QA field-by-field in addition to com-
plex analysis methods [20, 22]. The need for the so-
phisticated  treatment  plans  and  measurements  in-
creases if the tumor is located in an area surrounded 
by healthy and critical tissues. For example, a tumor 
in brain is surrounded by many organs at risk (OAR) 
such as the brain stem and the optic chiasm [10]. In 
our study we evaluated our QA system of IMRT plans 
that we use to treat patients with GBM.  
Presently,  we  perform  routine  QA  measure-
ments for each IMRT patient either immediately prior 
to the treatment or shortly after the first treatment, 
which is the protocol we use to avoid any delay for 
the treatment. The ten selected treatment plans were 
evaluated  using  2D-ARRAY  in  addition  to  inde-
pendent  monitor  unit  calculations  using  RadCal; 
however,  the  study  focused  only  on  the  measured 
dose by the ion chamber 2D-ARRAY. Figure 2 shows 
the plan dose calculated by TPS and Figure 3 shows 
the  measured  dose  by  the  2D-ARRAY.The  results 
showed agreement between the measurement dose by 
the 2D-ARRAY and the calculated dose produced by 
the TPS. Figure 4 shows the overlap of the planned 
dose and the measured dose using the gamma index. 
Every point measured in these plans agreed to within 
±3% acceptability criteria.  
 
Figure 2: The chart presenting the matrix of isodose line chamber readings failing the gamma-index criterion for the 
planned dose by the TPS where the fractional dose is was 2.192 Gy Int. J. Med. Sci. 2011, 8 
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Figure 3: This chart shows the matrix of isodose lines of the measured dose by the 2D-ARRAY where the fractional dose was 
2.185Gy 
 
Figure 4: This chart shows the matrix of isodose compression between the planned dose in PTS and the measured dose by 
2D-ARRAY ion chambers, where the matrix for the measured dose is shown in dashed lines. In this data 99% of the evaluated 
points passed. 
 
All the ten selected pretreatment plans were ac-
ceptable for clinical use. The evaluation of pretreat-
ment plans for IMRT QA is based on many factors 
such as patient position and patient immobilization 
and reproducibility; however, here we only evaluated 
the IMRT QA using the 2D-ARRAY ion chamber. All 
of  our  ten  selected  treatments  plans  successfully 
passed the gamma analysis criterion with more than 
97% pixels in every defined field size for each treat-
ment plan.  
Conclusion 
Patient specific dosimetric QA for IMRT plan is 
an important component of clinical usage of IMRT. 
Our result showed a very good agreement between 
measurements  dose  and  calculated  dose  which 
demonstrated  that  our  treatment  planning  using 
IMRT  is  accurately  done  compared  with  the  dose 
planned  by  the  TPS.  The  2D-ARRAY  ion  chamber 
measurement agreed with the planned dose, all the 
plans passed with >95% gamma criterion with pixels 
under  5%  dose  difference  and  3  mm  distance  to 
agreement for IMRT patient-specific quality assurance 
(QA).  A  good  consistency  was  observed  across  the 
treatments. We concluded that using 2D-ARRAY for 
IMRT  verification  plans  is  a  fast  method  and  pos-
sesses all the advantages of ionization chamber do-
simetry. Int. J. Med. Sci. 2011, 8 
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